ArticleBioengineering (Basel, Switzerland)2022
Cell Culture Process Scale-Up Challenges for Commercial-Scale Manufacturing of Allogeneic Pluripotent Stem Cell Products.
Article in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Stem Cell-Based Therapies for Central Nervous System Demyelinating Diseases: Clinical Evidence, Therapeutic Niches, and Translational Boundaries.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Induced pluripotent stem cells from discovery to translation.Nature medicine · 2026Review
- Harnessing intermediate-scale bioreactors for next-generation macrophage production and application.Nature protocols · 2026Review
- Gene-Edited Stem Cells for Ischemic Vascular Disease: Current Advances and Future Perspectives.Current issues in molecular biology · 2026Review
- Biopharmaceuticals for Cancer Treatment: An Update.Cancer medicine · 2026Review
- Engineering Stem Cells for Islet Replacement Therapy: Recent Advances and Barriers for Clinical Translation.Cells · 2026Review
- Microfluidics for cell therapy and manufacturing in oncology and regenerative medicine.Lab on a chip · 2026Review
- Winners take it all: turning cell competition into a therapeutic ally.Cell communication and signaling : CCS · 2026Review
- Non-Enzymatic Cell Expansion and Harvesting Using a Smart Thermo-Responsive Gel.Gels (Basel, Switzerland) · 2025Article
- AI-Driven Quality Monitoring and Control in Stem Cell Cultures: A Comprehensive Review.Biotechnology journal · 2025Review
- Modeling and Dynamic Parameterized Predictive Control of Dissolved Oxygen in Dual-Tank Bioreactor Systems.Bioengineering (Basel, Switzerland) · 2025Article
- Induced Pluripotent (iPSC) and Mesenchymal (MSC) Stem Cells for In Vitro Disease Modeling and Regenerative Medicine.International journal of molecular sciences · 2025Review
- Organoid culture promotes dedifferentiation of mouse myoblasts into stem cells capable of complete muscle regeneration.Nature biotechnology · 2025Article
- Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using Vertical Wheel® bioreactors.NPJ Regenerative medicine · 2025Article
- Expansion of induced pluripotent stem cells under consideration of bioengineering aspects: part 1.Applied microbiology and biotechnology · 2025Article
- Closed-system manufacturing of therapeutic NK cells using automated cell enrichment and concentration processes enables scalable, robust and cost-effective solutions.Frontiers in bioengineering and biotechnology · 2025Article
- Designing magnetic microcapsules for cultivation and differentiation of stem cell spheroids.Microsystems & nanoengineering · 2024Article
- The use of artificial intelligence in induced pluripotent stem cell-based technology over 10-year period: A systematic scoping review.PloS one · 2024Article
- Attachment promoting compounds significantly enhance cell proliferation and purity of bovine satellite cells grown on microcarriers in the absence of serum.Frontiers in bioengineering and biotechnology · 2024Article
- Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic cell therapy products, such as therapeutic cells derived from pluripotent stem cells (PSCs), have amazing potential to treat a wide variety of diseases and vast numbers of patients globally. However, there are various challenges related to manufacturing PSCs in single-use bioreactors, particularly at larger volumetric scales. This manuscript addresses these challenges and presents potential solutions to alleviate the anticipated bottlenecks for commercial-scale manufacturing of high-quality therapeutic cells derived from PSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.